EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN

S. Choquet; J. A. Pérez‐Simón; N. Worel; S. Chaganti; R. Dinavahi; N. Guzman‐Becerra; W. Navarro; Y. Sun; L. Gamelin

doi:10.1002/hon.170_2880

EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN

Hematological Oncology ◽

10.1002/hon.170_2880 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

S. Choquet ◽

J. A. Pérez‐Simón ◽

N. Worel ◽

S. Chaganti ◽

R. Dinavahi ◽

...

Keyword(s):

Study Design ◽

Epstein Barr Virus ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Barr Virus ◽

Phase 2 Study ◽

Open Label Phase ◽

Epstein Barr ◽

Adaptive Study Design

Download Full-text

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Previously Treated

Download Full-text

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study

10.1158/1538-7445.sabcs18-p6-20-07 ◽

2019 ◽

Author(s):

G Vidal ◽

K Kalinsky ◽

E Stringer-Reasor ◽

F Lynce ◽

J Cole ◽

...

Keyword(s):

Breast Cancer ◽

Small Molecule ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Molecule Inhibitor ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

European Journal of Cancer ◽

10.1016/j.ejca.2013.06.010 ◽

2013 ◽

Vol 49 (15) ◽

pp. 3219-3228 ◽

Cited By ~ 56

Author(s):

P. Schöffski ◽

D. Adkins ◽

J.-Y. Blay ◽

T. Gil ◽

A.D. Elias ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Previously Treated

Download Full-text

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

Expert Opinion on Biological Therapy ◽

10.1080/14712598.2021.1905794 ◽

2021 ◽

pp. 1-12

Author(s):

Suresh Kumar ◽

Rosemarie De Souza ◽

Milind Nadkar ◽

Randeep Guleria ◽

Anjan Trikha ◽

...

Keyword(s):

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Randomized Controlled ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study

International Journal of Hematology ◽

10.1007/s12185-019-02727-6 ◽

2019 ◽

Vol 110 (6) ◽

pp. 665-674 ◽

Cited By ~ 3

Author(s):

Takeshi Takahashi ◽

Kensuke Usuki ◽

Kosei Matsue ◽

Hitoshi Ohno ◽

Toru Sakura ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Japanese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Refractory Acute Myeloid Leukemia ◽

Acute Myeloid

Download Full-text

Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T-Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)

SSRN Electronic Journal ◽

10.2139/ssrn.3677881 ◽

2020 ◽

Author(s):

Yuankai Shi ◽

Jianqiu Wu ◽

Zhen Wang ◽

Liling Zhang ◽

Zhao Wang ◽

...

Keyword(s):

T Cell ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Peripheral T Cell Lymphoma ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2019.12.444 ◽

2020 ◽

Vol 26 (3) ◽

pp. S274

Author(s):

Susan E Prockop ◽

Minoti Hiremath ◽

Wei Ye ◽

Laurence Gamelin ◽

Willis H. Navarro ◽

...

Keyword(s):

Lymphoproliferative Disorder ◽

Epstein Barr Virus ◽

Organ Transplant ◽

Solid Organ Transplant ◽

Solid Organ ◽

Open Label ◽

Phase 3 ◽

Barr Virus ◽

Open Label Phase ◽

Epstein Barr

Download Full-text

Author response for "The efficacy and safety of Epstein‐Barr virus specific antigen peptide‐activated cytotoxic T cells treatment for refractory or recurrent angioimmunoblastic T cell lymphoma: A prospective clinical observational study"

10.1002/hon.2726/v2/response1 ◽

2020 ◽

Author(s):

Wang Bingjie ◽

Wang Lihong ◽

Shi Yongjin ◽

Liu Huihui ◽

Ou Jinping ◽

...

Keyword(s):

T Cells ◽

Epstein Barr Virus ◽

Cell Lymphoma ◽

Cytotoxic T Cells ◽

Specific Antigen ◽

Efficacy And Safety ◽

Angioimmunoblastic T Cell Lymphoma ◽

Barr Virus ◽

Antigen Peptide ◽

Epstein Barr

Download Full-text

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30788-0 ◽

2020 ◽

Vol 21 (2) ◽

pp. 207-221 ◽

Cited By ~ 72

Author(s):

Sagar Lonial ◽

Hans C Lee ◽

Ashraf Badros ◽

Suzanne Trudel ◽

Ajay K Nooka ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

29P ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy

Annals of Oncology ◽

10.1016/j.annonc.2020.10.515 ◽

2020 ◽

Vol 31 ◽

pp. S1426-S1427

Author(s):

N. Worel ◽

J.A. Perez-Simon ◽

P. Barba ◽

D. Dierickx ◽

M. Hiremath ◽

...

Keyword(s):

Lymphoproliferative Disease ◽

Phase Iii ◽

Solid Organ ◽

Cell Transplant ◽

Hematopoietic Cell Transplant ◽

Open Label ◽

Allogeneic Hematopoietic Cell Transplant ◽

Barr Virus ◽

Open Label Phase ◽

Epstein Barr

Download Full-text